4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow Adrian Vella: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics Saline, Exendin-9,39, Liraglutide - Healthy | Phase 3 | Completed | Adrian Vella | 21 | 2022-10-17 | 2026-10-28 |
| Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes Saline, Exendin-9,39, Saline + Intralipid/Heparin - Healthy, Type 2 Diabetes | Phase 3 | Completed | Adrian Vella | 23 | 2021-04-15 | 2023-12-26 |
| A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion Exendin-9,39, Saline - Healthy | Phase 3 | Completed | Adrian Vella | 11 | 2021-03-04 | 2023-06-09 |
| The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study - Healthy | Phase 3 | Completed | Adrian Vella | 12 | 2020-10-14 | 2022-06-21 |
Sodium Chloride (3) · Heparin (1) · Liraglutide (1) · soybean oil, phospholipid emulsion (1)
United States (4)
R01DK126206 (3)